Optimal Revascularization Time in Transient STEMI

Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients.

The aim of this study was to determine the effects of an immediate strategy, compared against a differed strategy, quantifying infarct size with cardiac magnetic resonance.

 

The study randomized 142 patients with transient ST elevation MI to immediate (as if it were primary PCI in persistent STEMI patients) mean 0.3 hours vs. invasive differed strategy (as non-STEMI patients) with mean 22.7 hours.



Read also: The Ten Commandments for the Fourth Universal Definition of Infarction.


Infarction size measured by CMR at day 4 after the event was small and similar between strategies.

 

Neither were there differences in terms of major cardiac events, a combination of death, reinfarction or revascularization at 30 days (2.9% vs. 2.8%, p=1.00).


Read also: Are Aortic Stenosis and Kidney Dysfunction Associated?


Only 4 patients in the deferred group (5.6%) required emergency intervention given their signs and symptoms while waiting the angiography.

 

Conclusion

Globally, infarct size in patients presenting transient ST elevation MI is small and revascularization strategy, whether immediate or differed, has no influence. Hard events at short term were low and similar between the groups.

 

Original title: Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Reference: Jorrit S. Lemkes et al. European Heart Journal (2019) 40, 283–291.

 

Infarto-elevacion-transitoria-st


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...

Calcified Nodules and Their Treatment with Rotational Atherectomy

Calcified nodules (CN) represent one of the most complex phenotypes to treat in coronary intervention. They are mainly associated with the need for repeat...

Complex PCI: higher ischemic and bleeding risk in contemporary practice

Advances in pharmacological therapies, equipment, and devices have enabled percutaneous coronary interventions (PCI) to be performed in a growing number of patients with a...

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...